Real-World Bosentan Therapy Successful in Pulmonary Arterial Hypertension: Presented at ATS PDF Print E-mail
Wednesday, 19 May 2010 19:52
Real-life experiences in treating patients with pulmonary arterial hypertension with bosentan appears to provide similar efficacy as seen in clinical trials -- despite patients being somewhat older and having more scleroderma, researchers said today here at the American Thoracic Society (ATS) 2010 International Conference.

"We also found that in our population of patients abnormal liver function tests were observed more often than in clinical trials," said Nathan Dwyer, MD, Pulmonary Medicine, Foothills Medical Center, Calgary, Alberta. He conducted his work at Royal Hobart Hospital, Hobart, Tasmania, Australia.

"Overall, we found that bosentan and other endothelin-receptor antagonists used to treat pulmonary arterial hypertension are effective in treating patients who may fall outside the tight criteria for patients in clinical trials," Dr. Dwyer said during his poster presentation.

He said that of the 152 patients treated in Tasmania, 23 patients developed abnormal liver function tests that required 20 of those patients to discontinue bosentan treatment. "You have to monitor these patients for liver function abnormalities very closely," he said.

Oedema also occurred frequently, occurring in 31 of his patients, but treatment with spironolactone was able to treat the oedema. Only 2 patients had to discontinue therapy due to oedema, he reported.

"The treated population differed from that in clinical trials by being older, having more Scleroderma, more comorbidities, and lower average walk distances," he said.

In the 6-minute walk test, subjects improved in their physical activity by about 60 metres from a baseline of about 300 metres. "We observed that this improvement was retained for at least 5 years," Dr. Dwyer said. The improvement was similar in those patients with idiopathic pulmonary arterial hypertension and in scleroderma pulmonary arterial hypertension.

"Bosentan was well tolerated and resulted in significant benefits over a 5-year period," he said. "These data represent what might be expected in a population including all morbidities."

The patients were followed from 2003 through 2008. The researchers achieved a 100% follow-up of these patients. Their mean age was 63 years, and 121 of the participants were women. All of the patients were in New York Heart Association class 3 or 4.

Funding for this study was provided by Actelion, CSL, and Bayer.

Source: Doctor's Guide
 
More articles :

» Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152

Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM152, the Company's oral selective antagonist of the LPA1 receptor.  Completion of this study positions Amira to initiate a Phase 2a study in...

» Curcumin May Have Therapeutic Value In Treating Scleroderma

Turmeric, a shrub related to ginger, is grown throughout India, other parts of Asia, and Africa. It is well known for its warm, bitter taste and golden yellow color. Turmeric is commonly used in fabric dyes and foods such as curry powders, mustards,...

» TLR4 Protein Implicated In The Fibrosis Associated With Scleroderma

An international multi-disciplinary research team led by scientists has uncovered a new role for the protein toll-like receptor 4 (TLR4) in the development of tissue fibrosis, or scarring.Recently reported in the , this finding has implications for...

» Endothelin Drugs Benefit Those With Pulmonary Hypertension

Breaking news from has reported that recent research to block the effects of endothelin, a powerful substance that constricts blood vessels and stimulates cell growth, has led to successful treatment of and provides hope for treating other chronic...

» ArGentis Seeks More Funding After Obtaining Patent for ARG201 Therapy

ArGentis Pharmaceuticals LLC has received a patent for its scleroderma therapy while finalizing plans for a Phase IIb trial for the treatment known as ARG201.The patent comes nearly two years after it was developed by University of Tennessee Health...

» Two Problems That People With Scleroderma Face: Malabsorption and Inflammation

According to , many doctors agree that starts with inflammation, and its progress depends on how much inflammation continues to occur in the body. That's one reason some doctors recommend that patients with any sort of inflammatory disease such as...